A.J. Grillo-López
About
In The Last Decade
A.J. Grillo-López
42 papers receiving 6.7k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Pathology and Forensic Medicine 4.3k
- Oncology 2.9k
- Genetics 2.7k
- Radiology, Nuclear Medicine and Imaging 2.5k
- Immunology 1.9k
Countries citing papers authored by A.J. Grillo-López
This map shows the geographic impact of A.J. Grillo-López's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.J. Grillo-López with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.J. Grillo-López more than expected).
Fields of papers citing papers by A.J. Grillo-López
This network shows the impact of papers produced by A.J. Grillo-López. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.J. Grillo-López. The network helps show where A.J. Grillo-López may publish in the future.
Co-authorship network of co-authors of A.J. Grillo-López
This figure shows the co-authorship network connecting the top 25 collaborators of A.J. Grillo-López. A scholar is included among the top collaborators of A.J. Grillo-López based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.J. Grillo-López. A.J. Grillo-López is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 23 | |
| 2 | 52 | |
| 3 | 54 | |
| 4 | 22 | |
| 5 | 17 | |
| 6 | Peripheral Blood B-Cell Recovery in Patients With Non-Hodgkin’s Lymphoma Treated With Rituximab Does Not Correlate With Onset of Disease Progression | 2 |
| 7 | 54 | |
| 8 | 118 | |
| 9 | Multicenter experience with the zevalin radiolabeling kit for radioimmunotherapy of non-hodgkin's lymphoma | 1 |
| 10 | 308 | |
| 11 | 85 | |
| 12 | Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. | 226 |
| 13 | 444 | |
| 14 | Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. breakdown → | 2153 |
| 15 | Development of response criteria (rc) for low-grade or follicular lymphomas (lg/f nhl) and application in a 166 patient study | 9 |
| 16 | IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. breakdown → | 527 |
| 17 | Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma breakdown → | 604 |
| 18 | 38 | |
| 19 | 9 | |
| 20 | 45 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.